1. Srivastava, G. & Apovian, C.M. Current pharmacotherapy for obesity. Nat. Rev. Endocrinol. 14, 12-24 (2018).
2. Manco, M., Putignani, L. & Bottazzo, G.F. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr. Rev. 31, 817-844 (2010).
3. Cani, P.D. et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57, 1470-1481 (2008).
4. Fei, N. & Zhao, L. An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. Isme J. 7, 880-884 (2013).
5. Udayappan, S. et al. Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice. Npj Biofilms Microbi. 2, 16009 (2016).
6. Plovier, H. et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat. Med. 23, 107-113 (2017).
7. Cani, PD. & de Vos, W.M. Next-generation beneficial microbes: the Case of Akkermansia muciniphila. Front. Microbiol. 8, 1765 (2017).
8. Wang, K. et al. Parabacteroides distasonis alleviates obesity and metabolic dysfunctions via production of succinate and secondary bile acids. Cell Rep. 26, 222-235 (2019).
9. Suarez-Zamorano, N. et al. Microbiota depletion promotes browning of white adipose tissue and reduces obesity. Nat. Med. 21, 1497-1501 (2015).
10. Richard, M.L. & Sokol, H. The gut mycobiota: insights into analysis, environmental interactions and role in gastrointestinal diseases. Nat. Rev. Gastro. Hepat. 16, 331-345 (2019).
11. Underhill, D.M. & Lliev, L.D. The mycobiota: interactions between commensal fungi and the host immune system. Nat. Rev. Immunol. 14, 405-416 (2014).
12. Borges, F.M. et al. Fungal diversity of human gut microbiota among eutrophic, overweight, and obese individuals based on aerobic culture-dependent approach. Curr. Microbiol. 75, 726-735 (2018).
13. Liu, T.T., Liu, X.T., Chen, Q.X. & Shi, Y. Lipase inhibitors for obesity: a review. Biomed. Pharmacother. 128, 110314 (2020).
14. Hamad, I. et al. Culturomics and amplicon-based metagenomic approaches for the study of fungal population in human gut microbiota. Sci. Rep. 7, 16788 (2017).
15. Yang, A.M. et al. Intestinal fungi contribute to development of alcoholic liver disease. J. Clin. Invest. 127, 2829-2841 (2017).
16. Kim, Y.G. et al. Gut dysbiosis promotes M2 macrophage polarization and allergic airway inflammation via fungi-induced PGE(2). Cell Host Microbe. 15, 95-102 (2014).
17. Jiang, T.T. et al. Commensal fungi recapitulate the protective benefits of intestinal bacteria. Cell Host Microbe. 22, 809-816 (2017).
18. Toth, R., Toth, A., Vagvolgyi, C. & Gacser, A. Candida parapsilosis secreted lipase as an important virulence factor. Curr. Protein Pept. Sc. 18, 1043-1049 (2017).
19. Hajri, T. & Abumrad, N.A. Fatty acid transport across membranes: relevance to nutrition and metabolic pathology. Annu. Rev. Nutr. 22, 383-415 (2002).
20. Petersen, C. et al. T cell-mediated regulation of the microbiota protects against obesity. Science 365, eaat9351 (2019).
21. Aguirre, M. & Venema, K. The art of targeting gut microbiota for tackling human obesity. Genes Nutr. 10, 20 (2015).
22. Membrez, M. et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. Faseb J. 22, 2416-2426 (2008).
23. Hoffmann, C. et al. Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. Plos One 8, e66019 (2013).
24. Mar Rodriguez, M. et al. Obesity changes the human gut mycobiome. Sci. Rep. 5, 14600 (2015).
25. Wang, T.T. et al. The adaptor protein CARD9 protects against colon cancer by restricting mycobiota-mediated expansion of myeloid-derived suppressor cells. Immunity 49, 504-514 (2018).
26. Sun, S.S. et al. Therapeutic manipulation of gut microbiota by polysaccharides of Wolfiporia cocos reveals the contribution of the gut fungi-induced PGE2 to alcoholic hepatic steatosis. Gut Microbes 12, 1830693 (2020).
27. Toth, A. et al. Secreted Candida parapsilosis lipase modulates the immune response of primary human macrophages. Virulence 5, 555-562 (2014).
28. Chung, H.J. et al. Intestinal removal of free fatty acids from hosts by Lactobacilli for the treatment of obesity. Febs. Open Bio. 6, 64-76 (2016).
29. Heck, A.M., Yanovski, J.A. & Calis, K.A. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 20, 270-279 (2000).
30. Wang, K. et al. Structural modification of natural product Ganomycin I leading to discovery of a α-glucosidase and HMG-CoA reductase dual inhibitor improving obesity and metabolic dysfunction in vivo. J. Med. Chem. 61, 3609-3625 (2018).
31. Reuss, O., Vik, A., Kolter, R. & Morschhauser, J. The SAT1 flipper, an optimized tool for gene disruption in Candida albicans. Gene 341, 119-127 (2004).
32. Gacser, A. et al. Targeted gene deletion in Candida parapsilosis demonstrates the role of secreted lipase in virulence. J. Clin. Invest. 117, 3049-3058 (2007).